Abstract:
MHC class I complexes can present antigenic peptides that have a sequence produced by post-translational mechanisms such as peptide splicing. Some examples of tumour-associated spliced epitopes have been investigated for their immunogenicity in the context of cancer so far. We developed several pipelines to identify and predict these noncanonical epitopes, which are freely available. In addition, we tested the immunogenicity and the potential for therapeutical applications for those associated to various forms of cancer.
